Low-dose valganciclovir for cytomegalovirus prophylaxis in organ transplantation: Is less really more?

Clinical Infectious Diseases

Volumn 52, Issue 3, 2011, Pages 322-324

  Avery, Robin K ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; VALACICLOVIR; VALGANCICLOVIR;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EVIDENCE BASED MEDICINE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG TRANSPLANTATION; META ANALYSIS (TOPIC); NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; ORGAN TRANSPLANTATION; TREATMENT OUTCOME;

EID: 79951839960     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq145     Document Type: Editorial

References (13)

1. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;143:870-80. (Pubitemid 46202222)
2. Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin Infect Dis 2010.
3. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. Jama 2003;289:2534-44. (Pubitemid 37430155)
4. Limaye AP. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients. Semin Respir Infect 2002;17:265-73. (Pubitemid 35453643)
5. Avery RK. Special considerations regarding CMV in lung transplantation. Transpl Infect Dis 1999;1(Suppl 1): 13):13-8.
6. Manez R, Kusne S, Green M, et al. Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Transplantation 1995;59:1010-14.
7. Schneeberger S, Lucchina S, Lanzetta M, et al. Cytomegalovirus-related complications in human hand transplantation. Transplantation 2005;80:441-7. (Pubitemid 41209410)
8. Drew WL. Ganciclovir resistance: a matter of time and titre. Lancet 2000;356:609-10. (Pubitemid 30627582)
9. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999;190:177-82. (Pubitemid 29354911)
10. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-20. (Pubitemid 38523584)
11. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000;356:645-9. (Pubitemid 30627592)
12. Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy 2004;24:1323-30. (Pubitemid 39304996)
13. Dupuis R, Harris M, Gillis K, et al. Expers with low-dose valganciclovir prophylaxis in adult liver transplant recipients. Transpl Proc 2007;39:3266-70. (Pubitemid 350251506)